BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

NCT00410059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]